Literature DB >> 20044204

Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder.

Ana Coelho1, Paolo Dinis, Rui Pinto, Tiago Gorgal, Carlos Silva, André Silva, João Silva, Célia D Cruz, Francisco Cruz, António Avelino.   

Abstract

BACKGROUND: Botulinum toxin type A (BoNTA) has been successfully used in the treatment of refractory detrusor overactivity. The toxin is internalized after binding a high-affinity receptor, synaptic vesicle protein 2 (SV2), which is exposed in the cell membrane during the exocytosis process. In the cytoplasm, BoNTA cleaves specific sites of synaptosomal-associated protein 25 (SNAP-25), preventing the assembly of the synaptic fusion complex SNARE and blocking exocytosis.
OBJECTIVE: In the present work, the distribution of SV2 and SNAP-25 was first investigated in human bladders. The neurochemistry of BoNTA-sensitive structures was then investigated using markers for parasympathetic, sympathetic, and sensory fibers. DESIGN, SETTING, AND PARTICIPANTS: Human bladders were obtained from cadaveric organ donors (age range: 19-74 yr). MEASUREMENTS: Bladder sections were processed for single or dual immunofluorescence staining with antibodies against SV2, SNAP-25, β-3 tubulin, vesicular acetylcholine transporter, tyrosine hydroxilase, and calcitonin gene-related peptide. RESULTS AND LIMITATIONS: SV2 and SNAP-25 immunoreactive fibers were distributed throughout the suburothelium and muscular layer. Double labeling showed extensive colocalization of both proteins in nerve fibers. SV2 is more expressed in parasympathetic fibers than in sympathetic or sensory fibers. No expression was found in urothelial or muscular cells. Because only normal bladders were used, this distribution should be applied with caution to pathologic bladders.
CONCLUSIONS: SV2 and SNAP-25 colocalize abundantly throughout the urinary bladder. SV2 is more abundant in cholinergic, parasympathetic fibers. These nerves are suggested to be the main target for BoNTA action in the human urinary bladder.
Copyright © 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20044204     DOI: 10.1016/j.eururo.2009.12.022

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  29 in total

Review 1.  Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.

Authors:  Todd A Linsenmeyer
Journal:  J Spinal Cord Med       Date:  2013-09       Impact factor: 1.985

Review 2.  A review of botulinum toxin use for chronic pelvic pain syndrome.

Authors:  Henry P Gottsch; Claire C Yang; Richard E Berger
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

Review 3.  [Botulinum toxin for neurogenic bladder dysfunction].

Authors:  H Schulte-Baukloh
Journal:  Urologe A       Date:  2012-02       Impact factor: 0.639

4.  Regulation of ACh release from guinea pig bladder urothelial cells: potential role in bladder filling sensations.

Authors:  L M McLatchie; J S Young; C H Fry
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

Review 5.  How botulinum toxin in neurogenic detrusor overactivity can reduce upper urinary tract damage?

Authors:  Maximilien Baron; Philippe Grise; Jean-Nicolas Cornu
Journal:  World J Nephrol       Date:  2016-03-06

Review 6.  Botulinum toxin injections for treating neurogenic detrusor overactivity.

Authors:  Ömer Bayrak; Erkan Sadioğlu; Rahmi Onur
Journal:  Turk J Urol       Date:  2015-12

7.  Expression of vesicular glutamate transporters in sensory and autonomic neurons innervating the mouse bladder.

Authors:  Pablo R Brumovsky; Rebecca P Seal; Kerstin H Lundgren; Kim B Seroogy; Masahiko Watanabe; G F Gebhart
Journal:  J Urol       Date:  2012-11-14       Impact factor: 7.450

8.  Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines.

Authors:  C Bandala; A L Cortés-Algara; C M Mejía-Barradas; I Ilizaliturri-Flores; R Dominguez-Rubio; C I Bazán-Méndez; E Floriano-Sánchez; J P Luna-Arias; M Anaya-Ruiz; E Lara-Padilla
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 9.  Understanding clinic options for overactive bladder.

Authors:  Jamie M Bartley; Emily S Blum; Larry T Sirls; Kenneth M Peters
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

Review 10.  Purinergic signalling in the urinary tract in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-11-22       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.